Epidemiological studies have identified numerous existing medications that appear to be associated with a reduced incidence or progression of Alzheimer’s disease. The literature surrounding these studies is confusing because of conflicting data. Retrospective epidemiological studies of both statins and nonsteroidal anti-inflammatory drugs (NSAIDs) show an association between medication use and a reduced incidence or progression of AD (Breitner et al., 1994; Jick, Zornberg, Jick, Seshadri, & Drachman, 2000; Wolozin, Kellman, Ruosseau, Celesia, & Siegel, 2000).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Aisen, P. S., Schafer, K. A., Grundman, M., Pfeiffer, E., Sano, M., Davis, K. L., et al. (2003). Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: A randomized controlled trial. The Journal of the American Medical Association, 289, 2819–2826.
Bi, X., Baudry, M., Liu, J., Yao, Y., Fu, L., Brucher, F., et al. (2004). Inhibition of geranylgeranylation mediates the effects of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors on microglia. The Journal of Biological Chemistry, 279, 48238–48245.
Breitner, J. C., Gau, B. A., Welsh, K. A., Plassman, B. L., McDonald, W. M., Helms, M. J., et al. (1994). Inverse association of anti-inflammatory treatments and Alzheimer' disease: Initial results of a co-twin control study. Neurology, 44, 227–232.
Breitner, J. C., Welsh, K. A., Helms, M. J., Gaskell, P. C., Gau, B. A., Roses, A. D., et al. (1995). Delayed onset of Alzheimer' disease with nonsteroidal anti-inflammatory and histamine H2 blocking drugs. Neurobiology of Aging, 16, 523–530.
Cole, S. L., Grudzien, A., Manhart, I. O., Kelly, B. L., Oakley, H., & Vassar, R. (2005). Statins cause intracellular accumulation of APP, beta-secretase cleaved fragments, and Abeta via an isoprenoid-dependent mechanism. The Journal of Biological Chemistry, 280, 18755–18770.
Cordle, A., Koenigsknecht-Talboo, J., Wilkinson, B., Limpert, A., & Landreth, G. (2005). Mechanisms of statin-mediated inhibition of small G-protein function. The Journal of Biological Chemistry, 280, 34202–34209.
Cordle, A., & Landreth, G. (2005). 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors attenuate beta-amyloid-induced microglial inflammatory responses. The Journal of Neuroscience, 25, 299–307.
Etminan, M., Gill, S., & Samii, A. (2003). Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer' disease: Systematic review and meta-analysis of observational studies. British Medical Journal, 327, 128.
Fassbender, K., Simons, M., Bergmann, C., Stroick, M., Lutjohann, D., Keller, P., et al. (2001). Simvastatin strongly reduces Alzheimer' disease Ab42 and Ab40 levels in vitro and in vivo. Proceedings of the National Academy of Sciences of the United States of America, 98, 5856–5861.
Heart Protection Study Collaborative Group. (2002). MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20, 536 high-risk individuals: A randomised placebo-controlled trial. Lancet, 360, 7–22.
Hernandez-Perera, O., Perez-Sala, D., Navarro-Antolin, J., Sanchez-Pascuala, R., Hernandez, G., Diaz, C., et al. (1998). Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. The Journal of Clinical Investigation, 101, 2711–2719.
Hoglund, K., Wiklund, O., Vanderstichele, H., Eikenberg, O., Vanmechelen, E., & Blennow, K. (2004). Plasma levels of beta-amyloid(1–40), beta-amyloid(1–42), and total beta-amyloid remain unaffected in adult patients with hypercholesterolemia after treatment with statins. Archives of Neurology, 61, 333–337.
Jick, H., Zornberg, G. L., Jick, S. S., Seshadri, S., & Drachman, D. A. (2000). Statins and the risk of dementia. Lancet, 356, 1627–1631.
Johnson, T. E., Zhang, X., Bleicher, K. B., Dysart, G., Loughlin, A. F., Schaefer, W. H., et al. (2004). Statins induce apoptosis in rat and human myotube cultures by inhibiting protein geranylgeranylation but not ubiquinone. Toxicology and Applied Pharmacology, 200, 237–250.
Johnson-Anuna, L. N., Eckert, G. P., Keller, J. H., Igbavboa, U., Franke, C., Fechner, T., et al. (2005). Chronic administration of statins alters multiple gene expression patterns in mouse cerebral cortex. The Journal of Pharmacology and Experimental Therapeutics, 312, 786–793.
Li, G., Higdon, R., Kukull, W. A., Peskind, E., Van Valen Moore, K., Tsuang, D., et al. (2004). Statin therapy and risk of dementia in the elderly: A community-based prospective cohort study. Neurology, 63, 1624–1628.
Lu, D., Goussev, A., Chen, J., Pannu, P., Li, Y., Mahmood, A., et al. (2004). Atorvastatin reduces neurological deficit and increases synaptogenesis, angiogenesis, and neuronal survival in rats subjected to traumatic brain injury. Journal of Neurotrauma, 21, 21–32.
Lutjohann, D., Stroick, M., Bertsch, T., Kuhl, S., Lindenthal, B., Thelen, K., et al. (2004). High doses of simvastatin, pravastatin, and cholesterol reduce brain cholesterol synthesis in guinea pigs. Steroids, 69, 431–438.
Marz, W., & Koenig, W. (2003). HMG-CoA reductase inhibition: Anti-inflammatory effects beyond lipid lowering? Journal of Cardiovascular Risk, 10, 169–179.
Masse, I., Bordet, R., Deplanque, D., Al Khedr, A., Richard, F., Libersa, C., et al. (2005). Lipid lowering agents are associated with a slower cognitive decline in Alzheimer' disease. Journal of Neurology, Neurosurgery, and Psychiatry, 76, 1624–1629.
McGeer, P. L., & McGeer, E. G. (1996). Anti-inflammatory drugs in the fight against Alzheimer' disease. Annals of the New York Academy of Sciences, 777, 213–220.
Park, I. H., Hwang, E. M., Hong, H. S., Boo, J. H., Oh, S. S., Lee, J., et al. (2003). Lovastatin enhances Abeta production and senile plaque deposition in female Tg2576 mice. Neurobiology of Aging, 24, 637–643.
Pedrini, S., Carter, T. L., Prendergast, G., Petanceska, S., Ehrlich, M. E., & Gandy, S. (2005). Modulation of statin-activated shedding of Alzheimer APP ectodomain by ROCK. PLos Medicine 2, e18.
Petanceska, S. S., DeRosa, S., Olm, V., Diaz, N., Sharma, A., Thomas-Bryant, T., et al. (2002). Statin therapy for Alzheimer' disease: Will it work? Journal of Molecular Neuroscience, 19, 155–161.
Refolo, L. M., Pappolla, M. A., LaFrancois, J., Malester, B., Schmidt, S. D., Thomas-Bryant, T., et al. (2001). A cholesterol-lowering drug reduces beta-amyloid pathology in a transgenic mouse model of Alzheimer' disease. Neurobiology of Disease, 8, 890–899.
Rejnmark, L., Buus, N. H., Vestergaard, P., Andreasen, F., Larsen, M. L., & Mosekilde, L. (2002). Statins decrease bone turnover in postmenopausal women: A cross-sectional study. European Journal of Clinical Investigation, 32, 581–589.
Rockwood, K., Kirkland, S., Hogan, D. B., MacKnight, C., Merry, H., Verreault, R., et al. (2002). Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people. Archives of Neurology, 59, 223–227.
Rogers, J., Kirby, L. C., Hempelman, S. R., Berry, D. L., McGeer, P. L., Kaszniak, A. W., et al. (1993). Clinical trial of indomethacin in Alzheimer' disease. Neurology, 43, 1609–1611.
Scharf, S., Mander, A., Ugoni, A., Vajda, F., & Christophidis, N. (1999). A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer' disease. Neurology, 53, 197–201.
Shepherd, J., Blauw, G. J., Murphy, M. B., Bollen, E. L., Buckley, B. M., Cobbe, S. M., et al. (2002). Pravastatin in elderly individuals at risk of vascular disease (PROSPER): A randomised controlled trial. Lancet, 360, 1623–1630.
Simons, M., Schwarzler, F., Lutjohann, D., Von Bergmann, K., Beyreuther, K., Dichgans, J., et al. (2002). Treatment with simvastatin in normocholesterolemic patients with Alzheimer' disease: A 26-week randomized, placebo-controlled, double- blind trial. Annals of Neurology, 52, 346–350.
Sjogren, M., Gustafsson, K., Syversen, S., Olsson, A., Edman, A., Davidsson, P., et al. (2003). Treatment with simvastatin in patients with Alzheimer' disease lowers both alpha- and beta-cleaved amyloid precursor protein. Dementia and Geriatric Cognitive Disorders, 16, 25–30.
Sparks, D. L., Sabbagh, M. N., Connor, D. J., Lopez, J., Launer, L. J., Browne, P., et al. (2005). Atorvastatin for the treatment of mild to moderate Alzheimer disease: Preliminary results. Archives of Neurology, 62, 753–757.
Vega, G. L., Weiner, M. F., Lipton, A. M., Von Bergmann, K., Lutjohann, D., Moore, C., et al. (2003). Reduction in levels of 24S-hydroxycholesterol by statin treatment in patients with Alzheimer disease. Archives of Neurology, 60, 510–515.
Wagstaff, L. R., Mitton, M. W., Arvik, B. M., & Doraiswamy, P. M. (2003). Statin-associated memory loss: Analysis of 60 case reports and review of the literature. Pharmacotherapy, 23, 871–880.
Weggen, S., Eriksen, J. L., Das, P., Sagi, S. A., Wang, R., Pietrzik, C. U., et al. (2001). A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature, 414, 212–216.
Wolozin, B., Kellman, W., Ruosseau, P., Celesia, G. G., & Siegel, G. (2000). Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Archives of Neurology, 57, 1439–1443.
Wolozin, B., Mange, J., Bryant, R., Cordy, J., Green, R., & McKee, A. (2006). Cholesterol, Alzheimer' disease and statins: Re-assessing the relationship between cholesterol, statins and Alzheimer' disease. Acta Neurologica Scandanavia, 185, 63–70.
Yaffe, K., Barrett-Connor, E., Lin, F., & Grady, D. (2002). Serum lipoprotein levels, statin use, and cognitive function in older women. Archives of Neurology, 59, 378–384.
Zacco, A., Togo, J., Spence, K., Ellis, A., Lloyd, D., Furlong, S., et al. (2003). 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors protect cortical neurons from excitotoxicity. The Journal of Neuroscience, 23, 11104–11111.
Zandi, P., Sparks, L., Khachaturian, A., Tschanz, J., Norton, M., Steinberg, M., et al. (2004). Do statins reduce risk of incident dementia and AD? The cache county study. Archives of General Psychiatry, 62, 217–224.
Zhang, F. L., & Casey, P. J. (1996). Protein prenylation: Molecular mechanisms and functional consequences. Annual Review of Biochemistry, 65, 241–269.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2007 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Wolozin, B. (2007). Interpreting Clinical Studies of Putative Therapeutics for Alzheimer's Disease: The Case of Statins and NSAIDs. In: Pharmacological Mechanisms in Alzheimer's Therapeutics. Springer, New York, NY. https://doi.org/10.1007/978-0-387-71522-3_18
Download citation
DOI: https://doi.org/10.1007/978-0-387-71522-3_18
Publisher Name: Springer, New York, NY
Print ISBN: 978-0-387-71521-6
Online ISBN: 978-0-387-71522-3
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)